COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic.
In: Gynecologic Oncology, Jg. 164 (2022-02-01), Heft 2, S. 304-310
academicJournal
Zugriff:
Despite significant increase in COVID-19 publications, characterization of COVID-19 infection in patients with gynecologic cancer remains limited. Here we present an update of COVID-19 outcomes among people with gynecologic cancer in New York City (NYC) during the initial surge of severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019 [COVID-19]). Data were abstracted from gynecologic oncology patients with COVID-19 infection among 8 NYC area hospital systems between March and June 2020. Multivariable logistic regression was utilized to estimate associations between factors and COVID-19 related hospitalization and mortality. Of 193 patients with gynecologic cancer and COVID-19, the median age at diagnosis was 65.0 years (interquartile range (IQR), 53.0–73.0 years). One hundred six of the 193 patients (54.9%) required hospitalization; among the hospitalized patients, 13 (12.3%) required invasive mechanical ventilation, 39 (36.8%) required ICU admission. Half of the cohort (49.2%) had not received anti-cancer treatment prior to COVID-19 diagnosis. No patients requiring mechanical ventilation survived. Thirty-four of 193 (17.6%) patients died of COVID-19 complications. In multivariable analysis, hospitalization was associated with an age ≥ 65 years (odds ratio [OR] 2.12, 95% confidence interval [CI] 1.11, 4.07), Black race (OR 2.53, CI 1.24, 5.32), performance status ≥2 (OR 3.67, CI 1.25, 13.55) and ≥ 3 comorbidities (OR 2.00, CI 1.05, 3.84). Only former or current history of smoking (OR 2.75, CI 1.21, 6.22) was associated with death due to COVID-19 in multivariable analysis. Administration of cytotoxic chemotherapy within 90 days of COVID-19 diagnosis was not predictive of COVID-19 hospitalization (OR 0.83, CI 0.41, 1.68) or mortality (OR 1.56, CI 0.67, 3.53). The case fatality rate among patients with gynecologic malignancy with COVID-19 infection was 17.6%. Cancer-directed therapy was not associated with an increased risk of mortality related to COVID-19 infection. • Gynecologic cancer patients with COVID-19 had a case fatality rate of 17.6% during the initial surge of the COVID-19 pandemic. • Hospitalization due to COVID-19 was associated with age ≥ 65 years, Black race, performance status ≥2 and ≥ 3 comorbidities. • Only former or current history of smoking \was associated with death due to COVID-19. • Recent immunotherapy use was not associated with hospitalization or death due to COVID-19 infection. [ABSTRACT FROM AUTHOR]
Titel: |
COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic.
|
---|---|
Autor/in / Beteiligte Person: | Lara, Olivia D. ; Smith, Maria ; Wang, Yuyan ; O'Cearbhaill, Roisin E. ; Blank, Stephanie V. ; Kolev, Valentin ; Carr, Caitlin ; Knisely, Anne ; McEachron, Jennifer ; Gabor, Lisa ; Chapman-Davis, Eloise ; Cohen, Seth ; Fehniger, Julia ; Lee, Yi-Chun ; Isani, Sara ; Liu, Mengling ; Wright, Jason D. ; Pothuri, Bhavana |
Zeitschrift: | Gynecologic Oncology, Jg. 164 (2022-02-01), Heft 2, S. 304-310 |
Veröffentlichung: | 2022 |
Medientyp: | academicJournal |
ISSN: | 0090-8258 (print) |
DOI: | 10.1016/j.ygyno.2021.12.004 |
Schlagwort: |
|
Sonstiges: |
|